Lyell Immunopharma (NASDAQ:LYEL) Earns Neutral Rating from HC Wainwright

Lyell Immunopharma (NASDAQ:LYEL)‘s stock had its “neutral” rating restated by HC Wainwright in a research note issued on Wednesday,Benzinga reports. They presently have a $1.00 target price on the stock. HC Wainwright’s price target indicates a potential upside of 117.96% from the company’s current price.

Lyell Immunopharma Stock Up 3.2 %

Shares of LYEL opened at $0.46 on Wednesday. Lyell Immunopharma has a twelve month low of $0.39 and a twelve month high of $2.88. The stock has a market capitalization of $135.45 million, a P/E ratio of -0.58 and a beta of -0.26. The company has a 50 day moving average of $0.57 and a 200-day moving average of $0.77.

Lyell Immunopharma (NASDAQ:LYEL) last released its earnings results on Wednesday, March 12th. The company reported ($0.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.52). Lyell Immunopharma had a negative net margin of 323,792.09% and a negative return on equity of 34.64%. The business had revenue of $0.01 million during the quarter. On average, sell-side analysts anticipate that Lyell Immunopharma will post -0.78 earnings per share for the current fiscal year.

Insider Activity at Lyell Immunopharma

In related news, Director Richard Klausner acquired 158,000 shares of the business’s stock in a transaction dated Friday, March 14th. The stock was bought at an average price of $0.60 per share, with a total value of $94,800.00. Following the acquisition, the director now owns 843,365 shares in the company, valued at $506,019. This represents a 23.05 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Charles W. Newton bought 200,000 shares of the firm’s stock in a transaction that occurred on Monday, March 17th. The stock was purchased at an average cost of $0.56 per share, with a total value of $112,000.00. Following the completion of the purchase, the chief financial officer now directly owns 200,000 shares of the company’s stock, valued at $112,000. This represents a ∞ increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 768,640 shares of company stock valued at $449,508. Insiders own 25.10% of the company’s stock.

Institutional Investors Weigh In On Lyell Immunopharma

Institutional investors and hedge funds have recently modified their holdings of the company. Decheng Capital LLC acquired a new position in Lyell Immunopharma during the fourth quarter worth approximately $7,622,000. Foresite Capital Management V LLC acquired a new position in shares of Lyell Immunopharma during the 4th quarter worth approximately $5,205,000. venBio Partners LLC bought a new stake in Lyell Immunopharma in the 4th quarter valued at $4,545,000. Renaissance Technologies LLC lifted its holdings in Lyell Immunopharma by 716.7% during the 4th quarter. Renaissance Technologies LLC now owns 1,612,146 shares of the company’s stock valued at $1,032,000 after purchasing an additional 1,414,746 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. acquired a new stake in Lyell Immunopharma during the 4th quarter valued at $887,000. 66.05% of the stock is owned by institutional investors.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.